{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-26-003510","form_type":"8-K","ticker":"ENTXW","cik":"0001638097","company_name":"Entera Bio Ltd.","filed_at":"2026-07-16T20:07:03+00:00","discovered_at":"2026-07-16T20:08:03.626030+00:00","generated_at":"2026-07-16T20:08:08.981644+00:00","sec_items":["5.02","5.07","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Entera Bio shareholders approve 2.5x increase in authorized shares to 350M and 2.5M share increase in equity plan","bullets":["Authorized ordinary shares increased from 140,010,000 to 350,000,000 effective July 14, 2026.","2018 Equity Incentive Plan amended to add 2,500,000 ordinary shares for issuance.","All director nominees elected: Sean Ellis, Steven D. Rubin, Geno H. Germano (Class III, three-year terms).","Shareholders approved non-executive director compensation, share-based grants, and advisory say-on-pay.","Kesselman & Kesselman (PwC) ratified as independent auditor for FY 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-003510","json":"https://secwatch.observer/filing/0001178913-26-003510.json","markdown":"https://secwatch.observer/filing/0001178913-26-003510.md","text":"https://secwatch.observer/filing/0001178913-26-003510.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638097/000117891326003510/0001178913-26-003510-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638097/000117891326003510/zk2635691.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-16T20:08:08.981644+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}